JP2008540519A - 生殖補助におけるオキシトシンのおよび/またはバソプレシンの拮抗薬の使用 - Google Patents
生殖補助におけるオキシトシンのおよび/またはバソプレシンの拮抗薬の使用 Download PDFInfo
- Publication number
- JP2008540519A JP2008540519A JP2008511075A JP2008511075A JP2008540519A JP 2008540519 A JP2008540519 A JP 2008540519A JP 2008511075 A JP2008511075 A JP 2008511075A JP 2008511075 A JP2008511075 A JP 2008511075A JP 2008540519 A JP2008540519 A JP 2008540519A
- Authority
- JP
- Japan
- Prior art keywords
- oxytocin
- vasopressin
- antagonists
- uterine
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003336 oxytocin antagonist Substances 0.000 title claims abstract description 64
- 229940121361 oxytocin antagonists Drugs 0.000 title claims abstract description 64
- 229940116211 Vasopressin antagonist Drugs 0.000 title claims abstract description 55
- 239000003038 vasopressin antagonist Substances 0.000 title claims abstract description 55
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title claims abstract description 49
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title claims abstract description 49
- 101800000989 Oxytocin Proteins 0.000 title claims abstract description 45
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 title claims abstract 8
- 239000003814 drug Substances 0.000 claims abstract description 60
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 50
- 238000012546 transfer Methods 0.000 claims abstract description 47
- 229940079593 drug Drugs 0.000 claims abstract description 38
- 230000009027 insemination Effects 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 239000000126 substance Substances 0.000 claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims description 42
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 19
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 19
- 229960003726 vasopressin Drugs 0.000 claims description 19
- 108010004977 Vasopressins Proteins 0.000 claims description 18
- 102000002852 Vasopressins Human genes 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- -1 1- (4-((N-acetyl-4-piperidinyl) oxy) -2-methoxybenzoyl) piperidin-4-yl Chemical group 0.000 claims description 13
- 239000005557 antagonist Substances 0.000 claims description 12
- 210000000287 oocyte Anatomy 0.000 claims description 12
- 230000002357 endometrial effect Effects 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 11
- 208000000509 infertility Diseases 0.000 claims description 11
- 230000036512 infertility Effects 0.000 claims description 11
- 231100000535 infertility Toxicity 0.000 claims description 11
- 230000001850 reproductive effect Effects 0.000 claims description 11
- 230000004720 fertilization Effects 0.000 claims description 8
- 229940125388 beta agonist Drugs 0.000 claims description 7
- 108700000551 ANTAG II Proteins 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 6
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 6
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 6
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 6
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 6
- 241001494479 Pecora Species 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 210000002257 embryonic structure Anatomy 0.000 claims description 6
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims description 6
- 229960001123 epoprostenol Drugs 0.000 claims description 6
- 229940040129 luteinizing hormone Drugs 0.000 claims description 6
- 239000002089 prostaglandin antagonist Substances 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 108700000560 ANTAG I Proteins 0.000 claims description 5
- 108700000544 ANTAG III Proteins 0.000 claims description 5
- 108010063183 L 365209 Proteins 0.000 claims description 5
- 108010082525 L 366948 Proteins 0.000 claims description 5
- 239000000556 agonist Substances 0.000 claims description 5
- 239000002840 nitric oxide donor Substances 0.000 claims description 5
- 241000283086 Equidae Species 0.000 claims description 4
- 241000282887 Suidae Species 0.000 claims description 4
- KSNUCNRMDYJBKT-UHFFFAOYSA-N n-[3-[4-[4-(2-oxo-3,4-dihydroquinolin-1-yl)piperidine-1-carbonyl]phenoxy]propyl]acetamide Chemical compound C1=CC(OCCCNC(=O)C)=CC=C1C(=O)N1CCC(N2C3=CC=CC=C3CCC2=O)CC1 KSNUCNRMDYJBKT-UHFFFAOYSA-N 0.000 claims description 4
- QHUGACUEEILSLD-NNWJBWDNSA-N (2s)-1-[(2r)-2-amino-3-(1h-imidazol-5-yl)propanoyl]-n-[(2r)-1-[[(2s,3s)-1-[(2s)-2-formyl-2-(piperidine-1-carbonyl)piperidin-1-yl]-3-methyl-1-oxopent-4-en-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@H](C=C)C)C(=O)N1[C@@](CCCC1)(C=O)C(=O)N1CCCCC1)C1=CN=CN1 QHUGACUEEILSLD-NNWJBWDNSA-N 0.000 claims description 3
- FYHBMPWRHCWNBC-KVARREAHSA-N 2-[(1r,4s)-3-bicyclo[2.2.1]heptanyl]acetic acid Chemical compound C1C[C@@H]2C(CC(=O)O)C[C@H]1C2 FYHBMPWRHCWNBC-KVARREAHSA-N 0.000 claims description 3
- UENRBNCNIZQNTR-XIFFEERXSA-N 4-chloro-3-[(3r)-5-chloro-1-[(2,4-dimethoxyphenyl)methyl]-3-methyl-2-oxoindol-3-yl]-n-ethyl-n-(pyridin-3-ylmethyl)benzamide Chemical compound C=1C=C(Cl)C([C@@]2(C)C3=CC(Cl)=CC=C3N(CC=3C(=CC(OC)=CC=3)OC)C2=O)=CC=1C(=O)N(CC)CC1=CC=CN=C1 UENRBNCNIZQNTR-XIFFEERXSA-N 0.000 claims description 3
- OXDZADMCOWPSOC-UHFFFAOYSA-N Argiprestocin Chemical compound N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 OXDZADMCOWPSOC-UHFFFAOYSA-N 0.000 claims description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 3
- 101800003024 Vasotocin Proteins 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- IFHSSGUGRIXWQU-UHFFFAOYSA-N l003147 Chemical compound N1C(=O)C2CCCN2C(=O)C(CC=2C=CC=CC=2)N(C)C(=O)C2CCC=NN2C(=O)C2CCC=NN2C(=O)C(C(C)CC)NC(=O)C1CC1=CC=CC=C1 IFHSSGUGRIXWQU-UHFFFAOYSA-N 0.000 claims description 3
- BADTYUHLCFJVTK-ZGAORZAOSA-N n-[1-[2-[[(2s)-1-amino-3-(3,4-dichlorophenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-5-oxohexanamide Chemical compound C12=CC=CC=C2N(CC(=O)N[C@@H](CC=2C=C(Cl)C(Cl)=CC=2)C(N)=O)C(=O)C(NC(=O)CCCC(=O)C)N=C1C1=CC=CC=C1 BADTYUHLCFJVTK-ZGAORZAOSA-N 0.000 claims description 3
- 229960003104 ornithine Drugs 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- ILLSOIRJMQNTIA-UHFFFAOYSA-N l004680 Chemical group N1C(=O)C2CCCCN2C(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C(CC=2C=C3C=CC=CC3=CC=2)NC(=O)C2CCCN2C(=O)C1CC1=CN=CN1 ILLSOIRJMQNTIA-UHFFFAOYSA-N 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 2
- YDPSKBZTMQDVAD-WAQYZQTGSA-N 4-chloro-3-[(3r)-5-chloro-1-[(2,4-dimethoxyphenyl)methyl]-3-methyl-2-oxoindol-3-yl]-n-ethyl-n-(pyridin-3-ylmethyl)benzamide;hydrochloride Chemical compound Cl.C=1C=C(Cl)C([C@@]2(C)C3=CC(Cl)=CC=C3N(CC=3C(=CC(OC)=CC=3)OC)C2=O)=CC=1C(=O)N(CC)CC1=CC=CN=C1 YDPSKBZTMQDVAD-WAQYZQTGSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 abstract description 22
- 229960001723 oxytocin Drugs 0.000 abstract description 20
- 102000004279 Oxytocin receptors Human genes 0.000 abstract description 7
- 108090000876 Oxytocin receptors Proteins 0.000 abstract description 7
- 230000009471 action Effects 0.000 abstract description 7
- 102000004136 Vasopressin Receptors Human genes 0.000 abstract description 5
- 108090000643 Vasopressin Receptors Proteins 0.000 abstract description 5
- 230000033228 biological regulation Effects 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract description 2
- 102400000050 Oxytocin Human genes 0.000 description 37
- 108700007535 atosiban Proteins 0.000 description 25
- VWXRQYYUEIYXCZ-OBIMUBPZSA-N atosiban Chemical compound C1=CC(OCC)=CC=C1C[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)CSSCCC(=O)N1 VWXRQYYUEIYXCZ-OBIMUBPZSA-N 0.000 description 25
- 229960002403 atosiban Drugs 0.000 description 25
- 230000000694 effects Effects 0.000 description 20
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 17
- 238000000034 method Methods 0.000 description 15
- 241000282412 Homo Species 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 12
- 230000008602 contraction Effects 0.000 description 10
- 230000035935 pregnancy Effects 0.000 description 10
- 230000019100 sperm motility Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 238000002604 ultrasonography Methods 0.000 description 8
- 230000001779 embryotoxic effect Effects 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 6
- 150000003180 prostaglandins Chemical class 0.000 description 6
- 108010057021 Menotropins Proteins 0.000 description 5
- 210000003679 cervix uteri Anatomy 0.000 description 5
- 231100000238 embryotoxicity Toxicity 0.000 description 5
- 210000004696 endometrium Anatomy 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000000754 myometrium Anatomy 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000004246 corpus luteum Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 208000005107 Premature Birth Diseases 0.000 description 2
- 206010042573 Superovulation Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 231100000351 embryotoxic Toxicity 0.000 description 2
- 210000005002 female reproductive tract Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 208000025661 ovarian cyst Diseases 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000007466 Male Infertility Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940083963 Peptide antagonist Drugs 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 208000034790 Twin pregnancy Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 206010003883 azoospermia Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000010143 cystone Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010252 digital analysis Methods 0.000 description 1
- 238000011496 digital image analysis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002458 fetal heart Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008182 oocyte development Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Abstract
Description
プラセボ‐対照の子宮収縮能(プラセボを投与されている患者における);VAS‐1、VAS‐2、VAS‐3−レルコバプタンを投与された患者における相対的(プラセボに対する)子宮収縮能:各番号は各バソプレシン投与に対応する。この図で示されているデータは、子宮収縮性を減少させる、バソプレシン受容体およびオキシトシン受容体の抑制効果を示している(バソプレシンおよびレルコバプタン両方が、オキシトシン受容体に同様に作用する。)。レルコバプタンの受容体特性(オキシトシン受容体と比較してバソプレシンV1a受容体に対するより大きな親和力)を、V1aの発現が妊婦と比較して非妊婦の子宮においてより多いという事実と一緒に考察すると、レルコバプタンは胚移植および人工授精前の適用に有望な候補である(Bossmarらの発表に記載の図[BJOG 1997,104;471−477])。
アトシバンを含有する薬剤は、ヒトにおける使用が公認された、今日まで唯一のオキシトシンおよびバソプレシンの拮抗薬である。これらはペプチド物質であり、生殖補助とは正反対に異なる状況(切迫早産)において妊娠を引き延ばすために使用されている、静脈注射での適用が公認されたものである。アトシバンの臨床での安全性は、公認に先立つ研究において十分に立証された。アトシバンは、比類なく安全であり、副作用は最小であると考えられている。しかしながら、アトシバンに関する胚毒性の研究は実施されていなかったため、生殖補助における使用は推定されていなかった。
Claims (26)
- 生殖補助用の薬剤を製造するための、オキシトシンの拮抗薬、オキシトシンおよびバソプレシンの拮抗薬もしくはバソプレシンの拮抗薬またはこれらの薬学的に許容される塩の使用。
- 製造された薬剤が、胚移植前、胚移植中および胚移植後に子宮腔内に適用され、前記薬剤が、子宮の受容性を向上させる、請求項1に記載の使用。
- 製造された薬剤が、子宮の収縮能の調節によって達成される子宮の受容性の向上および人工授精の成功率を増加させる子宮内膜の状態の向上に適用される、請求項1に記載の使用。
- オキシトシンの拮抗薬、オキシトシンおよびバソプレシンの拮抗薬もしくはバソプレシンの拮抗薬またはこれらの薬学的に許容される塩が、約0.01から約10gまでの24時間用量において適用される、請求項1に記載の使用。
- オキシトシンの拮抗薬、オキシトシンおよびバソプレシンの拮抗薬もしくはバソプレシンの拮抗薬またはこれらの薬学的に許容される塩が、ペプチドまたは非ペプチドである、請求項1に記載の使用。
- オキシトシンの拮抗薬、オキシトシンおよびバソプレシンの拮抗薬またはバソプレシンの拮抗薬が、以下のリストに記載の群:アトシバン、バルシバン、レルコバプタン、TT−235(ANTAG III、1−PMP(S)−2−Trp−6−Pen−8−Arg−オキシトシン)、L−365,209[シクロ(L−イソロイシル−D−2,3,4,5−テトラヒドロ−3−ピリダジンカルボニル−L−2,3,4,5−テトラヒドロ−3−ピリダジンカルボニル−N−メチル−D−フェニルアラニル−L−プロリル−D−フェニルアラニル]、L−366,509[2−ヒドロキシ−7,7−ジメチル−1−((スピロ(1H−インデン−1,4’−ピペリジン)−1’−イルスルホニル)メチル)ビシクロ(2.2.1)ヘプタン−2−酢酸],L−371,257[1−(1−(4−((N−アセチル−4−ピペリジニル)オキシ)−2−メトキシベンゾイル)ピペリジン−4−イル)−4H−3,1−ベンゾキサジン−2(1H)−オン]、L−372,662[1−(1−4−(1−(2−メチル−1−オキシドプリジン−3−イルメチル)ピペリジン−4−イルオキシル−2−メトキシベンゾイル)ピペリジン−4−イル)−1,4−ジヒドロベンズ(d)(1,3)オキサジン−2−オン]、L−368,899[1−(((7,7−ジメチル−2−(2−アミノ−4−(メチルスルホニル)ブチルアミド)ビシクロ(2.2.1)ヘプタン−1−イル)メチル)スルホニル)−4−(2−メチルフェニル)ピペラジン]、desGly(NH2)9d(CH2)5[Tyr(Me)2Thr4]OVT、 化合物PA1−6酸、ANTAG II(1−PMP−2−Trp−8−Arg−オキシトシン)、ANTAG I(1−PMP−2−Trp−3−Phe−4−Ile−8−Arg−オキシトシン)、L−366,948(シクロ(3−(2−ナフタレニル)−D−アラニル−L−イソロイシル−D−2−ピペリジンカルボニル−L−2−ピペリジンカルボニル−D−ヒスチジル−L−プロリル)、L−366,682(シクロ(D−ヒスチジル−L−プロリル−D−トリプトフィル−L−イソロイシル−D−2−ピペリジンカルボニル−L−2−ピペリジンカルボニル)、OTA(d(CH2)5[Tyr(Me)2Thr4,Tyr−NH2(9)]オルニチンバソトシン)、SSR126768A(4−クロロ−3−[(3R)−(+)−5−クロロ−1−(2,4−ジメトキシベンジル)−3−メチル−2−オキソ−2,3−ジヒドロ−1H−インドール−3−イル]−N−エチル−N−(3−ピリジルメチル)−ベンズアミド、塩酸塩)、GW405212Xとしてコードされた物質およびOPC−21268としてコードされた物質[1−(1−(4−(3−アセチルアミノプロポキシ)ベンゾイル)−4−ピペリジル)−3,4−ジヒドロ−2(1H)−キノリノン]から選択される物質である、請求項1に記載の使用。
- 製造された薬剤が、胚移植および/または人工授精に関連する、ヒトにおける不妊治療または動物における生殖補助のために利用される、請求項1に記載の使用。
- 胚移植が、新鮮胚または凍結/解凍胚の移植である、請求項1に記載の使用。
- 体外受精・胚移植(IVF−ET)の処置に関連する、請求項1に記載の使用。
- 卵母細胞または/および***がドナーから採取される、請求項1に記載の使用。
- 胚移植または人工授精が行われる、飼育動物における生殖補助の処置に関連する、請求項1に記載の使用。
- 飼育動物が、以下の群:ウシ、ブタ、ヒツジおよびウマから選択される、請求項1に記載の使用。
- 以下の群:酸化窒素供与体、酸化窒素シンターゼ基質、黄体ホルモン薬、プロスタグランジン拮抗薬、メチロキサンチン、ベータ作用薬、プロスタサイクリン作用薬からの他の薬剤の生殖補助における治療のための適用に関連する、請求項1に記載の使用。
- 有効物質および薬学的に許容される塩基を含有する、生殖補助用の薬剤であり、有効物質として以下の群:オキシトシンの拮抗薬、オキシトシンおよびバソプレシンの拮抗薬もしくはバソプレシンの拮抗薬またはこれらの薬学的に許容される塩からの物質を含有する、前記薬剤。
- 胚移植前、胚移植中、および胚移植後の適用のために指定され、子宮の受容性を向上させる、請求項14に記載の薬剤。
- 子宮の収縮能の調節により達成される子宮の受容性の向上および人工授精の成功率を増加させる子宮内膜の状態の向上のために指定される、請求項14に記載の薬剤。
- 有効物質の量が、約0.01mgから約10gまでの24時間用量を示す、請求項14に記載の薬剤。
- 有効物質が、ペプチドまたは非ペプチドである、請求項14に記載の薬剤。
- オキシトシンの拮抗薬またはオキシトシンおよびバソプレシンの拮抗薬またはバソプレシンの拮抗薬が、以下のリストに記載の群:アトシバン、バルシバン、レルコバプタン、TT−235(ANTAG III、1−PMP(S)−2−Trp−6−Pen−8−Arg−オキシトシン)、L−365,209[シクロ(L−イソロイシル−D−2,3,4,5−テトラヒドロ−3−ピリダジンカルボニル−L−2,3,4,5−テトラヒドロ−3−ピリダジンカルボニル−N−メチル−D−フェニルアラニル−L−プロリル−D−フェニルアラニル)、L−366,509[2−ヒドロキシ−7,7−ジメチル−1−((スピロ(1H−インデン−1,4’−ピペリジン)−1’−イルスルホニル)メチル)ビシクロ(2.2.1)ヘプタン−2−酢酸]、L−371,257[1−(1−(4−((N−アセチル−4−ピペリジニル)オキシ)−2−メトキシベンゾイル)ピペリジン−4−イル)−4H−3,1−ベンゾキサジン−2(1H)−オン]、L−372,662[1−(1−4−(1−(2−メチル−1−オキシドプリジン−3−イルメチル)ピペリジン−4−イルオキシル−2−メトキシベンゾイル)ピペリジン−4−イル)−1,4−ジヒドロベンズ(d)(1,3)オキサジン−2−オン]、L−368,899[1−(((7,7−ジメチル−2−(2−アミノ−4−(メチルスルホニル)ブチルアミド)ビシクロ(2.2.1)ヘプタン−1−イル)メチル)スルホニル)−4−(2−メチルフェニル)ピペラジン]、desGly(NH2)9d(CH2)5[Tyr(Me)2Thr4]OVT、化合物PA1−6酸、ANTAG II(1−PMP−2−Trp−8−Arg−オキシトシン)、ANTAGI(1−PMP−2−Trp−3−Phe−4−Ile−8−Arg−オキシトシン)、L−366,948(シクロ(3−(2−ナフタレニル)−D−アラニル−L−イソロイシル−D−2−ピペリジンカルボニル−L−2−ピペリジンカルボニル−D−ヒスチジル−L−プロリル)、L−366,682(シクロ(D−ヒスチジル−L−プロリル−D−トリプトフィル−L−イソロイシル−D−2−ピペリジンカルボニル−L−2−ピペリジンカルボニル)、OTA(d(CH2)5[Tyr(Me)2Thr4,Tyr−NH2(9)]オルニチンバソトシン)、SSR126768A(4−クロロ−3−[(3R)−(+)−5−クロロ−1−(2,4−ジメトキシベンジル)−3−メチル−2−オキソ−2,3−ジヒドロ−1H−インドール−3−イル]−N−エチル−N−(3−ピリジルメチル)−ベンズアミド、塩酸塩)、GW405212Xとしてコードされた物質およびOPC−21268としてコードされた物質[1−(1−(4−(3−アセチルアミノプロポキシ)ベンゾイル)−4−ピペリジル)−3,4−ジヒドロ−2(1H)−キノリノン]から選択される物質である、請求項14に記載の薬剤。
- 胚移植または人工授精を対象とする、ヒトにおける不妊治療または動物における生殖補助のために指定される、請求項14に記載の薬剤。
- 胚移植が、新鮮胚または凍結/解凍胚の移植である、請求項20に記載の薬剤。
- 体外受精・胚移植法(IVF−ET)による不妊の治療のために指定される、請求項20に記載の薬剤。
- 卵母細胞または/および***がドナーから採取される、請求項20に記載の薬剤。
- 胚移植または人工授精により治療される飼育動物における生殖補助のために指定される、請求項20に記載の薬剤。
- 飼育動物が、以下のリストに記載の群:ウシ、ブタ、ヒツジおよびウマからである、請求項24に記載の薬剤。
- 以下の群:酸化窒素供与体、酸化窒素シンターゼ基質、黄体ホルモン薬、プロスタグランジン拮抗薬、メチロキサンチン(methyloxanthines)、ベータ作用薬、プロスタサイクリン作用薬から選択される、生殖補助における治療のための他の物質をさらに含有する、請求項14に記載の薬剤。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PLP.374954 | 2005-05-10 | ||
PL374954A PL374954A1 (pl) | 2005-05-10 | 2005-05-10 | Zastosowanie antagonistów oksytocyny lub antagonistów oksytocyny i wazopresyny lub antagonistów wazopresyny do wytwarzania leków stosowanych podczas procedur wspomaganego rozrodu |
PLP.376607 | 2005-08-12 | ||
PL376607A PL376607A1 (pl) | 2005-08-12 | 2005-08-12 | Zastosowanie antagonistów oksytocyny i/lub wazopresyny |
US73391605P | 2005-11-04 | 2005-11-04 | |
US60/733,916 | 2005-11-04 | ||
PCT/PL2006/000029 WO2006121362A2 (en) | 2005-05-10 | 2006-05-10 | Use of antagonists of oxytocin and/or vasopressin in assisted reproduction |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008540519A true JP2008540519A (ja) | 2008-11-20 |
JP4762308B2 JP4762308B2 (ja) | 2011-08-31 |
Family
ID=37056586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008511075A Expired - Fee Related JP4762308B2 (ja) | 2005-05-10 | 2006-05-10 | 生殖補助におけるオキシトシンのおよび/またはバソプレシンの拮抗薬の使用 |
Country Status (20)
Country | Link |
---|---|
US (1) | US20080318847A1 (ja) |
EP (1) | EP1879572B1 (ja) |
JP (1) | JP4762308B2 (ja) |
KR (1) | KR100985449B1 (ja) |
CN (1) | CN101646436B (ja) |
AT (1) | ATE507830T1 (ja) |
AU (1) | AU2006244693B2 (ja) |
CA (1) | CA2605923C (ja) |
DE (1) | DE602006021736D1 (ja) |
DK (1) | DK1879572T3 (ja) |
ES (1) | ES2366130T3 (ja) |
IL (1) | IL186595A (ja) |
MX (1) | MX2007014022A (ja) |
NO (1) | NO340956B1 (ja) |
NZ (1) | NZ562409A (ja) |
PL (1) | PL1879572T3 (ja) |
PT (1) | PT1879572E (ja) |
RU (1) | RU2385735C2 (ja) |
SI (1) | SI1879572T1 (ja) |
WO (1) | WO2006121362A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018505212A (ja) * | 2014-12-22 | 2018-02-22 | フェリング・ベー・フェー | 生殖補助医療を受けている女性における着床及び妊娠のための黄体期のオキシトシン受容体アンタゴニスト療法 |
JP2019523251A (ja) * | 2016-07-21 | 2019-08-22 | オブセヴァ エス.エー. | 胚着床を促進し、流産を防ぐためのオキシトシンアンタゴニスト投与レジメン |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103417475B (zh) * | 2013-06-27 | 2015-06-17 | 深圳翰宇药业股份有限公司 | 一种巴鲁西班注射液及其制备方法 |
EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
MX371068B (es) | 2014-07-02 | 2020-01-15 | ObsEva SA | ((3z,5s)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil ]pirrolidin-3-ona o-metiloxima cristalina y métodos de uso de la misma. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US962413A (en) * | 1909-05-13 | 1910-06-28 | George Hillard Benjamin | Method of soldering chains. |
US5948762A (en) * | 1993-07-16 | 1999-09-07 | Schering Aktiengesellschaft | Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor or a nitric oxide inhibitor |
US5599809A (en) * | 1994-09-29 | 1997-02-04 | Merck & Co., Inc. | Method for improving reproductive efficiency in farm animals |
US20010056068A1 (en) * | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
FR2807038B1 (fr) * | 2000-04-03 | 2002-08-16 | Sanofi Synthelabo | Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant |
-
2006
- 2006-05-10 ES ES06747719T patent/ES2366130T3/es active Active
- 2006-05-10 US US11/914,049 patent/US20080318847A1/en not_active Abandoned
- 2006-05-10 NZ NZ562409A patent/NZ562409A/en not_active IP Right Cessation
- 2006-05-10 WO PCT/PL2006/000029 patent/WO2006121362A2/en active Application Filing
- 2006-05-10 KR KR1020077025706A patent/KR100985449B1/ko active IP Right Grant
- 2006-05-10 AU AU2006244693A patent/AU2006244693B2/en not_active Ceased
- 2006-05-10 DK DK06747719.0T patent/DK1879572T3/da active
- 2006-05-10 PT PT06747719T patent/PT1879572E/pt unknown
- 2006-05-10 CN CN2006800568367A patent/CN101646436B/zh not_active Expired - Fee Related
- 2006-05-10 EP EP06747719A patent/EP1879572B1/en active Active
- 2006-05-10 RU RU2007140702/15A patent/RU2385735C2/ru active
- 2006-05-10 JP JP2008511075A patent/JP4762308B2/ja not_active Expired - Fee Related
- 2006-05-10 MX MX2007014022A patent/MX2007014022A/es active IP Right Grant
- 2006-05-10 AT AT06747719T patent/ATE507830T1/de active
- 2006-05-10 PL PL06747719T patent/PL1879572T3/pl unknown
- 2006-05-10 SI SI200631039T patent/SI1879572T1/sl unknown
- 2006-05-10 CA CA2605923A patent/CA2605923C/en not_active Expired - Fee Related
- 2006-05-10 DE DE602006021736T patent/DE602006021736D1/de active Active
-
2007
- 2007-10-11 IL IL186595A patent/IL186595A/en active IP Right Grant
- 2007-12-10 NO NO20076328A patent/NO340956B1/no not_active IP Right Cessation
Non-Patent Citations (4)
Title |
---|
JPN5008006380, LESNY P, BJOG:AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 200411, V111 N11, P1182−1189, GB * |
JPN5008006386, PIERZYNSKI P, JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 200409, V11 N6, P384−387, US, ELSEVIER * |
JPN6010064028, British Journal of Obstetrics and Gynaecology, 1986, vol.93, p.22−27 * |
JPN6010064029, Acta Obstetricia et Gynecologica Scandinavica, 2004, vol.83, p.12−18 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018505212A (ja) * | 2014-12-22 | 2018-02-22 | フェリング・ベー・フェー | 生殖補助医療を受けている女性における着床及び妊娠のための黄体期のオキシトシン受容体アンタゴニスト療法 |
JP2021054863A (ja) * | 2014-12-22 | 2021-04-08 | フェリング・ベー・フェー | 生殖補助医療を受けている女性における着床及び妊娠のための黄体期のオキシトシン受容体アンタゴニスト療法 |
JP7184935B2 (ja) | 2014-12-22 | 2022-12-06 | フェリング・ベー・フェー | 生殖補助医療を受けている女性における着床及び妊娠のための黄体期のオキシトシン受容体アンタゴニスト療法 |
JP2019523251A (ja) * | 2016-07-21 | 2019-08-22 | オブセヴァ エス.エー. | 胚着床を促進し、流産を防ぐためのオキシトシンアンタゴニスト投与レジメン |
JP7036791B2 (ja) | 2016-07-21 | 2022-03-15 | オブセヴァ エス.エー. | 胚着床を促進し、流産を防ぐためのオキシトシンアンタゴニスト投与レジメン |
JP2022078194A (ja) * | 2016-07-21 | 2022-05-24 | オブセヴァ エス.エー. | 胚着床を促進し、流産を防ぐためのオキシトシンアンタゴニスト投与レジメン |
Also Published As
Publication number | Publication date |
---|---|
AU2006244693A1 (en) | 2006-11-16 |
CN101646436A (zh) | 2010-02-10 |
IL186595A0 (en) | 2008-01-20 |
NO20076328L (no) | 2007-12-10 |
KR100985449B1 (ko) | 2010-10-05 |
EP1879572A2 (en) | 2008-01-23 |
DK1879572T3 (da) | 2011-07-04 |
IL186595A (en) | 2013-10-31 |
PT1879572E (pt) | 2011-08-23 |
WO2006121362A3 (en) | 2007-05-03 |
CN101646436B (zh) | 2012-07-18 |
RU2007140702A (ru) | 2009-06-20 |
CA2605923C (en) | 2012-07-24 |
PL1879572T3 (pl) | 2011-10-31 |
ES2366130T3 (es) | 2011-10-17 |
MX2007014022A (es) | 2008-02-07 |
DE602006021736D1 (de) | 2011-06-16 |
ATE507830T1 (de) | 2011-05-15 |
EP1879572B1 (en) | 2011-05-04 |
CA2605923A1 (en) | 2006-11-16 |
JP4762308B2 (ja) | 2011-08-31 |
SI1879572T1 (sl) | 2011-07-29 |
RU2385735C2 (ru) | 2010-04-10 |
AU2006244693B2 (en) | 2010-11-04 |
NZ562409A (en) | 2011-02-25 |
US20080318847A1 (en) | 2008-12-25 |
KR20070118186A (ko) | 2007-12-13 |
NO340956B1 (no) | 2017-07-31 |
WO2006121362A2 (en) | 2006-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7153824B2 (en) | Inhibitors of phosphodiesterases in infertility | |
JP4762308B2 (ja) | 生殖補助におけるオキシトシンのおよび/またはバソプレシンの拮抗薬の使用 | |
JP2002220346A (ja) | 哺乳動物における生殖能力改善のためのpdev阻害薬の使用 | |
Gurgan et al. | Intravenous calcium infusion as a novel preventive therapy of ovarian hyperstimulation syndrome for patients with polycystic ovarian syndrome | |
US9585854B2 (en) | N-acetyl-L-cysteine for use in in vitro fertilization | |
JP6959371B2 (ja) | 純粋な5−ht6受容体アンタゴニストの新たな使用 | |
ES2283541T3 (es) | Inhibicion de aromatasa para mejorar el indice de implantacion. | |
US20070010525A1 (en) | Method and compositions for modulating neuropeptide hormone secretion | |
CZ20011524A3 (cs) | Pouľití thiazolidindionových derivátů pro prevenci děloľních stahů u předčasného porodu nebo laktace | |
ZA200507228B (en) | Inhibitors of phosphodiesterases in infertility | |
JP2019523251A (ja) | 胚着床を促進し、流産を防ぐためのオキシトシンアンタゴニスト投与レジメン | |
JP4342516B2 (ja) | 子宮内胎児発育遅延又は妊娠中毒症の予防又は治療剤 | |
TW202402291A (zh) | 投予貝魯舒地爾治療患者亞群的慢性移植物抗宿主病的方法 | |
Donderwinkel et al. | Methotrexate in management of advanced ectopic pregnancy complicated by ovarian hyperstimulation syndrome | |
Dhume | Comparative study between intrauterine insemination following preovulatory perturbation versus intrauterine insemination alone in induced ovulation cycles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20090722 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090724 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110214 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110510 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110607 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140617 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4762308 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |